Galmed Pharmaceuticals Ltd (NASDAQ: GLMD)’s stock price has plunge by -1.41relation to previous closing price of 1.42. Nevertheless, the company has seen a -4.11% plunge in its stock price over the last five trading sessions. prnewswire.com reported 2025-04-10 that – AM-001 Study represents a pivotal milestone in Galmed’s transition to Aramchol Meglumine, an improved formulation of its lead compound in advanced clinical development – Aramchol Meglumine, a New Chemical Entity (NCE) protected by patents until 2035, is being developed both as a standalone agent and in novel drug combinations for multiple indications influenced by fatty acid metabolism – Initial findings suggest that the new Aramchol Meglumine formulation offers higher bioavailability than Aramchol free acid and that a once-daily, oral 200 mg dose is likely to be optimal for future trials, supporting improved patient compliance and potentially lowering manufacturing costs TEL AVIV, Israel, April 10, 2025 /PRNewswire/ — Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (“Galmed” or the “Company”), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine.
Is It Worth Investing in Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Right Now?
The 36-month beta value for GLMD is at 0.47. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for GLMD is 2.22M, and currently, shorts hold a 3.07% of that float. The average trading volume for GLMD on April 10, 2025 was 864.15K shares.
GLMD’s Market Performance
The stock of Galmed Pharmaceuticals Ltd (GLMD) has seen a -4.11% decrease in the past week, with a -20.92% drop in the past month, and a -52.38% fall in the past quarter. The volatility ratio for the week is 12.15%, and the volatility levels for the past 30 days are at 16.05% for GLMD. The simple moving average for the last 20 days is -19.69% for GLMD stock, with a simple moving average of -58.12% for the last 200 days.
Analysts’ Opinion of GLMD
Many brokerage firms have already submitted their reports for GLMD stocks, with B. Riley FBR repeating the rating for GLMD by listing it as a “Neutral.” The predicted price for GLMD in the upcoming period, according to B. Riley FBR is $8 based on the research report published on May 22, 2020 of the previous year 2020.
Craig Hallum, on the other hand, stated in their research note that they expect to see GLMD reach a price target of $18. The rating they have provided for GLMD stocks is “Buy” according to the report published on February 04th, 2020.
Cantor Fitzgerald gave a rating of “Overweight” to GLMD, setting the target price at $14 in the report published on January 30th of the previous year.
GLMD Trading at -33.65% from the 50-Day Moving Average
After a stumble in the market that brought GLMD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.12% of loss for the given period.
Volatility was left at 16.05%, however, over the last 30 days, the volatility rate increased by 12.15%, as shares sank -16.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.17% lower at present.
During the last 5 trading sessions, GLMD fell by -3.75%, which changed the moving average for the period of 200-days by -62.28% in comparison to the 20-day moving average, which settled at $1.7436. In addition, Galmed Pharmaceuticals Ltd saw -56.11% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GLMD
The total capital return value is set at -0.37. Equity return is now at value -49.77, with -42.80 for asset returns.
Currently, EBITDA for the company is -6.87 million with net debt to EBITDA at 1.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.42.
Conclusion
In conclusion, Galmed Pharmaceuticals Ltd (GLMD) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
